Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome

5Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Although thalidomide is a U.S. Food and Drug Admistration (FDA) approved medication for erythema nodosum leprosum and multiple myeloma, it has many off-label uses, including for discoid lupus erythematosus (DLE), Behçet’s disease, apththous ulcers in HIV patients, and prurigo nodularis. Herein, we present a patient with an overlap of discoid lupus erythematosus and lichen planus who was successfully treated with thalidomide for over 19 years without significant side effects. We propose that some of the most common side effects, including peripheral neuropathy, numbness, parasthesias, sedation, and constipation, can be avoided at lower doses, typically less than 100mg/day.

Cite

CITATION STYLE

APA

Zhang, L., Au, S., & Aronson, I. K. (2014). Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome. Dermatology Online Journal. Dermatology Online Journal. https://doi.org/10.5070/d32010024267

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free